A number of studies have demonstrated that the STAT pathway is an important signaling cascade utilized by the IL-6 cytokine family to regulate a variety of cell functions. However, the downstream target genes of STAT activation that mediate the cytokine-induced cellular responses are largely uncharacterized. The aims of the current study are to determine whether the STAT signaling pathway is critically involved in the oncostatin M (OM)-induced growth inhibition and morphological changes of MCF-7 cells and to identify STAT3-target genes that are utilized by OM to regulate cell growth and morphology. We show that expression of a dominant negative (DN) mutant of STAT3 in MCF-7 cells completely eliminated the antiproliferative activity of OM, whereas expression of DN STAT1 had no effect. The growth inhibition of breast cancer cells was achieved through a concerted action of OM on cell cycle components. We have identified four cell cycle regulators including c-myc, cyclin D1, c/EBPd, and p53 as downstream effectors of the OM-activated STAT3 signaling cascade. The expression of these genes is differentially regulated by OM in MCF-7 cells, but is unaffected by OM in MCF-7-dnStat3 stable clones. We also demonstrate that the OM-induced morphological changes are correlated with increased cell motility in a STAT3-dependent manner. Expression analysis of extracellular matrix (ECM) proteins leads to the identification of fibronectin as a novel OM-regulated ECM component. Our studies further reveal that STAT3 plays a key role in the robust induction of fibronectin expression by OM in MCF-7 and T47D cells. These new findings provide a molecular basis for the mechanistic understanding of the effects of OM on cell growth and migration.
Introduction
STAT proteins are important signaling molecules for many cytokines, such as IL-6 family cytokines (Hirano et al., 1997; Heinrich et al., 1998) , and numerous growth factors, including EGF (Leaman et al., 1996) . STAT proteins possess dual functions that not only transmit a signal from the cell surface to the nucleus after cytokine engagement of cognate cell surface receptors, but also regulate gene expression by direct binding to STATrecognition sequence in the promoter region of the target genes . Although seven members of the STAT family have been characterized in mammalian cells, in general only a single STAT protein or a subset of family members is specifically activated by individual cytokines.
STAT3 and STAT1 are the main STAT proteins activated by the IL-6 cytokine family in a variety of cell types including hepatocytes (Kiuchi et al., 1999; Li et al., 2002; Marsters et al., 2002) , chondrocytes (Catterall et al., 2001) , astrocytes (Schaefer et al., 2000) , endothelial cells (Mahboubi and Pober, 2002) , glioblastoma cells (Halfter et al., 2000) , melanoma cells (Kortylewski et al., 1999) , and breast cancer cells (Badache et al., 2001; Li et al., 2001a, b; Grant et al., 2002) . A number of recent studies have shown that activation of STAT3 and STAT1 by the same cytokine, such as oncostatin M (OM), leads to different biological outcomes in different cell types, suggesting that the expression of genetic programs initiated by STAT activation is heavily influenced by cellular context.
OM is a member of IL-6 cytokine family produced by activated T cells and macrophages (Zarling et al., 1986; Brown et al., 1987; Grove et al., 1991) . Similar to IL-6 or LIF, OM is pleiotropic and participates in diversified cellular processes such as wound healing (Duncan et al., 1995; Bamber et al., 1998) , inflammatory response (Wahl and Wallce, 2001) , and cellular proliferation and differentiation (Douglas et al., 1997; Liu et al., 1997; Horn et al., 1990; Grove et al., 1993; Zhang et al., 1994; Halfter et al., 1998) . OM manifests its function through specific binding to OM receptors, including the OMspecific receptor (OSMR) and the LIF receptor (LIFR). Additions of OM to cells in culture immediately induce the dimerization of receptor subunits, OSMRb and GP130. This results in phosphorylation and activation of receptor-associated JAK family kinases, leading to activation of several intracellular signaling pathways. Although the STAT1 and STAT3 proteins and the MAP kinase ERK are coactivated simultaneously by OM in every cell type that expresses the OM-high-affinity receptor (OSMR), there are conflicting reports as to which signaling cascade is critically linked to a defined OM-induced cellular functional change.
Previously, we have shown that the OM-induced growth suppression and morphological changes of breast cancer cell line MDA-MB231 can be totally abrogated by blocking ERK activation with the MAP kinase kinase-1 (MEK-1) inhibitors (Li et al., 2001a, b, c) . By contrast, MEK inhibitors PD98059 and U0126 were not able to abolish the OM antiproliferative activity or to reverse the morphological changes in MCF-7 cells, implying that other signaling pathways activated by OM in MCF-7 cells are responsible for its actions.
It has been reported in several studies that the OM antiproliferative activity is accompanied by the induction of morphological changes of breast cancer cells Spence et al., 1997; Douglas et al., 1998; Halfter et al., 1998) . In general, the OM-treated cells displayed disrupted intercellular cell junctions. Cells became scattered. The morphological changes could be partially attributed to cellular differentiation, as the accumulation of neutral lipid, a marker of differentiation, was detected in OM-treated MCF-7 cells (Douglas et al., 1998; Grant et al., 2002) . However, a recent study conducted in T47D cells has suggested that the scattered phenotype is associated with an increased cell migration towards OM (Badache and Hynes, 2001 ). OM, acted as a chemoattractant, induced T47D cells to migrate in the absence of STAT3 activation. The mechanisms that underlie the effect of OM on cell migration of T47D cells remain elusive.
The aims of the current study are to determine whether the STAT signaling pathway is critically involved in the OM-induced growth inhibition and morphological changes of MCF-7 cells and to identify STAT3-target genes that are utilized by OM to regulate cell growth and motility.
Result
Blockade of OM-induced STAT3 and STAT1 transactivation by dominant negative STAT mutant proteins OM activates both STAT3 and STAT1 in MCF-7 cells. To determine whether STAT3 or STAT1 activation is a key event in the OM-induced growth inhibition of MCF-7 cells, we established stable MCF-7 clones that express a dominant negative STAT3 mutant (dnStat3, Y705F) or a dominant negative STAT1 mutant (dnStat1, Y701F). MCF-7 clones (neo) transfected with the empty vector (pEFneo) were also generated and were used in this study as negative controls to access the possible side effects associated with antibiotic selection.
To determine the effect of mutant STAT proteins on OM-induced STAT DNA binding activity, gel shift and supershift assays using a 32 P-labeled oligonucleotide probe (c-FosSIE), containing the high-affinity STAT3 binding site of c-fos gene promoter, were performed with nuclear extracts prepared from MCF-7 stable clones that were untreated or treated with OM for 15 min. As shown in Figure 1a , in MCF-7-neo cells, OM induced the formation of three specific DNA-protein complexes (lane 2). Supershift assays with antibodies specific to STAT1 or to STAT3 showed that the complex C3 was completely supershifted by anti-STAT1 antibody (lane 3), suggesting that C3 is the homodimer of STAT1. The C2 complex was supershifted by both anti-STAT1 and anti-STAT3 (lane 5), thereby demonstrating that C2 is the heterodimer of STAT1 and STAT3. The lowintensity band C1 was completely supershifted by anti-STAT 3 antibody (lane 4), demonstrating its identity as the STAT3 homodimer. The OM-induced STAT binding activity was markedly reduced in clones of dnStat3 (lanes 8-11) and dnStat1 (lanes 12-15) as compared to the neo clone (lanes 1-7) and untransfected MCF-7 cells (data not shown). Low levels of STAT1 binding activity were observed in uninduced neo (lane 1) and dnStat3 (lane 8) clones, suggesting that some of the STAT1 protein exist in a constitutively activated form in MCF-7 cells.
To further demonstrate a blockade of STAT3 transactivating activity by the mutant dnStat3 a STAT3 luciferase reporter (pTKlucS3) was transiently transfected into MCF-7-neo and dnStat3 clones. Cells, 40 h after transfection, were treated with OM for 4 h and luciferase activities were measured. As shown in Figure 1b , OM induced an eight-fold increase in the promoter activity of pTKlucS3 in the neo clone, but this induction was completely abolished in the clone of dnStat3.
We next examined the effect of OM on ERK activation in MCF-7 and stable clones. Western blot analysis detected comparable levels of activated ERK in parental MCF-7 cells and stable clones (Figure 2) . These results clearly demonstrate that expression of the DN STATs specifically abolished STAT DNA binding and transactivating activity without subverting the OMinduced MEK/ERK signaling pathway.
Expression of dnStat3 but not dnStat1 abolished the antiproliferative activity of OM The impact of dnStat3 or dnStat1 expression on OMinduced growth suppression was first evaluated by cell proliferation assays that measured the binding of a fluorescent dye to cellular nucleic acids, which produces fluorescent signals in proportion to the cell number. Figure 3a shows that the cellular proliferation of MCF-7, the neo clones, and the clones expressing dnStat1 was inhibited by 60-75% as compared to control after incubation with OM for 5 days, whereas the growth rate of dnStat3 clones was unaffected by OM. To further Figure 1 Blocking STAT DNA binding and transactivation by STAT mutant proteins. (a) EMSA analyses of nuclear proteins interacting with the STAT binding site. Nuclear extracts were prepared from MCF-7-neo clone, pEFneo-dnStat1 clone, and pEFdnStat3 clone that were untreated (lanes 1), or treated with OM (15 min) (lanes 2-15). A double-stranded oligonucleotide, designated as c-FosSIE, was radiolabeled and incubated with 10 mg of nuclear extract per reaction for 10 min at 221C in the absence (lanes 1, 2, 7, 8, 14, 15) or presence of 100-fold molar amounts of unlabeled competitor DNA (lanes 6, 7, 13, 14, 20, 21) . For supershift, antibodies were incubated with nuclear extracts at 221C for 30 min prior to the addition of the probe. The reaction mixtures were loaded onto a 6% polyacrylamide gel and run in TGE buffer at 30 mA for 3 h at 41C. (b) Analysis of STAT3 reporter luciferase activity. The STAT3 reporter pLucTKS3 was cotransfected with pRL-SV40 into neo or dnStat3 clones. Cells, 40 h after transfection, were treated either with OM (50 ng/ml) or with OM dilution buffer for 4 h prior to harvesting cell lysates. Luciferase activities in total cell lysates were measured using the Promega Dual Luciferase Assay System. Absolute firefly luciferase activity was normalized against renilla luciferase activity to correct for transfection efficiency. The normalized luciferase activity is expressed as the fold of luciferase activity in untreated control cells. The data presented are derived from three separate transfections in which triplicate wells were used in each condition Figure 2 Activation of MAP kinases ERK1 and ERK2 by OM in MCF-7 and stable clones. MCF-7, neo, dnStat1, and dnStat3 clones cultured in medium containing 0.5% FBS were stimulated with 50 ng/ml OM. At the indicated times, cells were scraped into lysis buffer and cell extracts were prepared. Soluble proteins (30 mg/lane) were applied to SDS-PAGE. Detection of phosphorylated ERK1 and ERK2 and the nonphosphorylated ERK2 was performed by immunoblotting Oncostatin M-activated STAT3 signaling pathway F Zhang et al verify the blocking effect of DN STAT3 on OM growth inhibitory activity, a time course of cell growth rate in the absence or the presence of OM was conducted by direct accounting of the viable cell numbers of MCF-7 cells and the dnStat3 clone. Figure 3b shows that OM exerted a time-dependent inhibitory effect on MCF-7 cells. By 7 days of the OM treatment, the number of viable cells was decreased by more than 50% as compared to control. Consistent with the results of Figure 3a , the growth of dnStat3 cells was not inhibited by OM through the entire duration of the experiment. These results demonstrate that expression of the dominant negative mutant of STAT3 but not STAT1 blocked the OM-mediated growth arrest in MCF-7 cells.
OM regulates c-myc gene expression through STAT3-dependent and independent mechanisms
c-myc is a potent oncogene, the expression level of which is directly correlated with cellular growth status (Kelly et al., 1983; Carroll et al., 2002) . Recent studies further identify c-myc as a target gene of STAT3 (Kiuchi et al., 1999; Bowman et al., 2001) . OM and IL-6 regulates c-myc mRNA expression in a biphasic manner with an early induction and a subsequent suppression (Liu et al., 1992 Minami et al., 1996; Spence et al., 1997) . To determine the role of STAT3 in OM-regulated transcription of c-myc, Northern blot analysis was conducted to detect levels of the c-myc mRNA after short and long exposures to OM in MCF-7 and stable clones. Figure 4a shows that OM treatment over a 3-day time course decreased the levels of c-myc mRNA by 60-80% in MCF-7, neo, and dnStat1 clones but not in dnStat3 clones. Interestingly, contrary to the long exposure, the transient induction of c-myc mRNA by OM was not abolished by overexpression of dnStat3 or dnStat1 ( Figure 4b ). A brief incubation of cells with OM stimulated c-myc expression to comparable levels (2-4 fold) in the MCF-7, neo, dnStat1, and the dnStat3 clones. These results suggest that OM downregulates c-myc transcription through a STAT3-dependent mechanism, whereas the immediate effect of OM on upregulation of c-myc is independent of the STAT3 signaling cascade.
Identification of STAT3 target genes c/EBPd and cyclin D1 as novel OM-regulated genes that participate in OMmediated growth repression
Previous investigations have shown that OM treatment resulted in an accumulation of breast cancer cells in the G 0 /G 1 phase of the cell cycle (Douglas et al., 1998; Grant et al., 2002) . The molecular mechanisms underlying the OM effects on cell cycle have not been clearly defined. Since cyclin D1 (Sinibaldi et al., 2000; Sauter et al., 2002) and c/EBPd (Yamada et al., 1997) are known target genes of STAT3 activation, and their gene products are important regulators in the G 0 /G1 phase of the cell cycle, we sought to determine whether OM regulates cyclin D1 and c/EBPd in MCF-7 cells and whether this regulation requires STAT3 activity. Figure 5 shows that OM reciprocally modulates cyclin D1 and c/EBPd expression. OM increased c/EBPd protein expression to levels of three-to fivefold of control in MCF-7, the neo, and dnStat1 clones, whereas the c/EBPd expression in dnStat3 cells was not induced by OM (Figure 5a ). The expression of cyclin D1 was inhibited by OM in MCF-7 cells and this inhibition was (Figure 5b ). These results demonstrate that OM exerts its effect on cell growth by direct regulation of critical cell cycle components through the STAT3 signaling pathway.
STAT3 participates in OM-mediated downregulation of p53
OM downregulates p53 expression in MCF-7 cells by inhibiting the gene transcription (Liu et al., 1999; Li et al., Figure 4 Detection of c-myc mRNA expression in MCF-7, neo, dnStat1 and dnStat3 clones by Northern blot analysis. Cells cultured in 60 mm dishes were treated with OM for 1-3 days (a) or for a short period of time (b). By the end of treatment, cells were lysed and total RNA was isolated. Total RNA of 15 mg per sample was analysed for c-myc mRNA by Northern blot. The membrane was stripped and rehybridized to a human GAPDH cDNA probe. The figure shown is representative of three separate experiments Figure 5 Western blot analyses of c/EBPd and cyclin D1 protein expressions in MCF-7 and stable clones. Cells cultured in medium containing 2% FBS were incubated with 50 ng/ml OM for the indicated times and total cell lysate was harvested at the end of treatment. Soluble proteins (50 mg/lane) were applied to SDS-PAGE. Detections of c/EBPd (a) and cyclin D1 (b) were performed by immunoblotting and autoradiography. Immunoblotting of the membranes with anti-b-actin mAb was conducted to normalize the amounts of protein being analysed Oncostatin M-activated STAT3 signaling pathway F Zhang et al 2001a, b, c) . Since blocking the MEK/ERK pathway only partially reversed the OM inhibitory effect on p53 protein expression, it is possible that other signaling pathways could also be involved. To evaluate the role of STAT3 in p53 transcription, a p53 promoter luciferase reporter construct pGL3-p53 was cotransfected with pEF-dnStat3 or with a control vector (pEFneo) into MCF-7 cells along with pRL-SV40 for normalization of variations in transfection efficiency. Cells were treated with OM or OM dilution buffer for 40 h and dual luciferase activities were measured in total cell lysates. The p53 promoter activity was decreased by 50% in OM-treated cells in the absence of pEF-dnStat3. Expression of dnStat3 reversed the OM inhibitory effect on p53 promoter activity (Figure 6a ). We further examined p53 protein levels in MCF-7 neo and dnStat3 clones untreated or treated with OM. Western blot analysis shows that while OM treatment lowered p53 protein level to 35% of control in the neo clone, the level of p53 protein in the dnStat3 clone was not decreased by OM treatment (Figure 6b ). Taken together, these results demonstrate that activation of STAT3 signaling pathway is a necessary step in the OM-mediated regulation of p53 transcription.
OM-induced morphological changes are associated with increased cell motility and expression of fibronectin in a STAT3-dependent manner Figure 7 shows OM-induced morphological changes that appeared in MCF-7, neo clone, and dnStat1 clone, but not in dnStat3 clones. The tight cell-to-cell junctions in MCF-7 cells was severely disrupted by OM. Cells became flat and larger, and also developed cell extensions and membrane protrusions. These changes subtly surfaced after 1 day of OM treatment and were predominant after 3 days. However, in dnStat3 clones morphological changes were not readily detected even after 5 days. After a longer period of culture (7 days) in the presence of OM, slight morphological changes were noticed. The OM-induced morphological changes were reversible, as cells slowly resumed original cell shape after withdrawal of OM from the culture medium.
We were interested to know whether the OM-induced phenotype is related to changes in the extracellular matrix (ECM) composition. Using Western blot analysis, we examined several ECM proteins including P-cadeherin, E-cadeherin, and fibronectin that are known to play important roles in cell morphology and migration. We found that the protein level of Ecadeherin was not changed by OM and the level of P-cadeherin was only slightly increased after OM treatment (data not shown). In contrast, OM induced a robust time-dependent expression of fibronectin in MCF-7 cells and a much weak induction of fibronectin in the dnStat3 clone (Figure 8a ). To determine whether the effect of OM on fibronectin expression is confined to MCF-7 cells, we examined fibronectin expression in another two breast cancer cell lines T47D and SKBR-3 to which OM also induces similar morphological changes (data not shown). Figure 8b shows that the expression of fibronectin in these two cell lines were strongly induced by OM as well. Moreover, the induction of fibronectin by OM was not detected in T47D-dnStat3 cells that stably express the dnStat3 mutant ( Figure 8c ) and these cells failed to show the distinct morphological changes upon OM treatment. These results strongly suggest that fibronectin is a downstream effector of the OM-activated STAT3 signaling cascade and expression of fibronectin may change the cell morphology.
Finally, we examined the involvement of STAT3 pathway in cell migration. Boyden chamber assays were performed to examine the direct effect of OM on cell motility. Cells were pretreated with OM for different days, trypsinized, counted, and seeded onto the top chamber; cells were then allowed to migrate through the membrane in the absence of any chemoattractant. As shown in Figure 9a , OM induced a time-dependent increase in the number of migrated cells. After a 2-day treatment, the number of migrated cells increased more than 12-fold of control. To determine the involvement of STAT3 in this newly discovered property of OM, the migration assay was conducted using DN STAT3 cells that were untreated or treated Figure 9b shows that the cell motility of dnStat3 clones was not stimulated at all even after 6 days of OM treatment.
Previously, using OM as a chemoattractant added to the bottom chamber, Badache et al has shown that expression of DN STAT3 did not affect the migration of T47D cells (Badache and Hynes, 2001 ). To determine whether DN STAT3 expression in MCF-7 cells is able to block the cell migration towards OM, MCF-7 and the dnStat3 clone were directly seeded onto the top chambers without prior exposure to OM. OM or its dilution buffer as control was added to the bottom chambers. Cells were allowed to migrate for 24 h and the migrated cells were stained and counted. Figure 9c shows that OM as a chemoattractant induced the migration of dnStat3 clone and MCF-7 to similar extents. This corroborated the observation made in T47D cells. Thus, our results, for the first time, demonstrate that OM affects the intrinsic cell motility through a STAT3-dependent mechanism, whereas the Figure 7 Detection of OM-induced morphological changes in MCF-7, neo, and dnStat1 clones but not in the dnStat3 clone. Cells were cultured in medium containing 2% FBS with or without OM for 3-5 days. Photographs were taken at the indicated time of OM treatment by using the Penguin 600CL digital camera at a magnification of 200. The loss of OM-induced morphological changes in T47D-dnStat3 cells was also observed Oncostatin M-activated STAT3 signaling pathway F Zhang et al mechanism of chemoattraction mediated by OM is independent of STAT signaling pathway.
Discussion
The STAT pathway and the MEK/ERK pathway are two major signaling cascades utilized by IL-6 cytokine family to elicit a variety of biological response (Heinrich et al., 1998) . Depending on cell types, activation of the same pathway can lead to different biological outcomes. It is conceivable that the downstream targets of ERK or STAT are differentially activated in different cell lines. Each signaling pathway may regulate a unique set of genes whose functions dictate the outcome induced by the cytokine in a cell line-specific manner. From this point of view, identification of target genes of a specific signaling cascade is of importance. It can provide insight to understand the mechanisms of cytokine's action at the molecular levels and may help predict outcomes in an uncharacterized system.
In this study, by utilizing dominant negative mutants of STAT3 and STAT1 we demonstrate that STAT3 but not STAT1 activation is a critical event in the OMmediated growth inhibition of MCF-7 cells. Our results are consistent with the finding in A375 melonoma cells whose growth was strongly inhibited by OM in a STAT3 but not a STAT1-depdendent mechanism (Kortylewski et al., 1999) . While it has been shown that STAT1 activation by IL-4 results in reduced growth rates in human colon carcinoma cell lines (Chang et al., 2000) , it appears that activation of Stat1 by OM alone does not lead to changes in gene transcription and cell function. However, since blocking STAT3 DNA binding activity could affect the binding activity of STAT1 protein, our data cannot absolutely rule out the functional role of STAT1 in OM signaling. Additional experiments to block STAT3 and STAT1 expression by different approaches will be needed to reach a firm conclusion.
Recent investigations have identified c-myc as the downstream effector of STAT3 signaling (Kiuchi et al., 1999; Bowman et al., 2001) . By using the dnStat3 clone, we found that the OM-induced biphasic regulation of c-myc is both STAT3-dependent and STAT3-independent. Our finding that dnStat3 blocks the OM-induced suppression of c-myc transcription recapitulates the observation obtained previously in M1 cells (Minami et al., 1996) . It was shown that IL-6-induced downregulation of c-myc in M1 cells was obviated by dnStat3 expression. Unexpectedly, the rapid induction of c-myc mRNA expression by OM in MCF-7 cells was not affected by dnStat3. The induction of c-myc mRNA (three-to four fold of control) by OM was completely abolished by actinomycin D (data not shown), implying a nature of transcriptional activation. The E2F binding site of the c-myc promoter, located at +98 to +106 bp, was shown to interact with STAT3 and to mediate the inducing activity of IL-6 on c-myc promoter activity (Kiuchi et al., 1999) . We have analysed a series of c-myc promoter luciferase reporters that contain the wild-type E2F or the mutated E2F sites in a transient transfection system of MCF-7 cells. We did not observe a significant induction of the c-myc promoter activity by OM regardless of the status of the E2F site (our unpublished data). Our results suggest that OM may stimulate c-myc transcription through some regulatory mechanisms such as chromatin remodeling that might not be readily accessed by the transient transfection of plasmid DNA. The mechanisms underlying the STAT3-independent activation of c-myc transcription by OM is currently under investigation in our laboratory.
In addition to c-myc, we have identified another two cell cycle regulators, c/EBPd and cyclin D1, that function in the G 0 /G1 phase of the cell cycle. c/EBPd has an important role in the induction of G 0 growth arrest in mammary epithelial cells (Hutt et al., 2000) and cyclin D1 expression promotes cell cycle progression (Sherr and Roberts, 1999) . OM through the STAT3 signaling cascade coordinately regulates the expression of c/EBPd and cyclin D1. Although the direct role of these proteins individually in the OM-mediated growth arrest of MCF-7 cells has not been demonstrated in this Figure 8 Western blot analysis for fibronection expression. The effects of OM on fibronectin expression were examined in wild-type STAT3 and the dnStat3 clones. MCF-7, MCF7-dnStat3 (a), T47D, SKBR-3 (b) cells were treated with OM. At the indicated time, cell was harvested and total cell lysates of 50 mg per sample were used to analyse fibronectin expression by Western blot analysis. In (c), T47D and T47D-dnStat3 cells were cultured in the absence (control) or presence of OM for 4 days and the expression of fibronection was examined by Western blot using total cell lysate. Data are expressed as fold increase relative to control Oncostatin M-activated STAT3 signaling pathway F Zhang et al study, we postulate that the reduced growth rate of MCF-7 cells results from a concerted regulatory action of OM on several cell cycle components, leading to an accumulation of cells at the G 0 /G1 phase.
Recently, there is emerging information to link STAT3 signaling pathway with p53. It was shown that the expression of the wild-type p53 in breast cancer cells inhibited STAT3-dependent transcriptional activity OM increases the intrinsic cell motility through the STAT3-signaling cascade. The effects of OM on cell motility were examined in MCF-7 and the dnStat3 clone. In (a), MCF-7 cells were pretreated with OM for different days at a concentration of 50 ng/ ml. At the end of treatment, cells were trypsinized and counted. Cells were then seeded onto the top chamber at a density of 0.15 Â 10 6 per chamber. The top chamber and the bottom chamber both contained 2% FBS RPMI. Migrated cells were counted after 6 h. In (b), MCF-7 and MCF7-dnStat3 cells were cultured in the absence (control) or presence of OM for 6 days. The ability of cell to migrate was determined as described in (a). In (c), cells without prior exposure to OM were seeded onto the top chamber which contained 2% FBS RPMI. OM at a concentration of 50 ng/ml was added to the bottom chamber that contained 2% FBS RPMI. Cells were allowed to migrate towards OM for 24 h. The migrated cells were fixed, stained, and counted. Data are expressed as fold increase relative to control Oncostatin M-activated STAT3 signaling pathway F Zhang et al (Lin et al., 2002) . Another reporter showed that Hep3B cells stably expressing a temperature-sensitive p53 species (p53-Val-135) displayed a reduced response to IL-6 when cultured at the wild-type p53 permitting temperature (Rayanade et al., 1997) . Later studies revealed that the reduction of cellular response to IL-6 was because of a p53-caused masking of STAT3 and STAT5, but not STAT1 (Rayanade et al., 1998) . In this study, we showed that blocking STAT3 activity by dnStat3 reversed the OM inhibitory effect on p53 transcription, demonstrating an involvement of STAT3 in OM-mediated negative regulation of the p53 transcription. Our previous investigation has identified the regulatory sequence (PE21) of p53 promoter as the OMresponsive element that mediates the OM effect on p53 transcription (Li et al., 2001a, b, c) . However, we did not detect STAT3 in the protein complex bound to the PE21 region by supershift using anti-STAT3 antibody (our unpublished data). This is not surprising, as the sequence of PE21 motif is not related to the STAT canonical sequence (Noda et al., 2000) . We speculate that the effect of STAT3 on p53 transcription is likely indirect and might be mediated through other downstream effectors of STAT3. Nevertheless, our novel finding that STAT3 participates in p53 transcription brings new insight into the interaction between the STAT signaling machinery and p53. It is possible that a reciprocal interaction exists: p53 regulates STAT3 phosphorylation and transactivating activity and the STAT3 affects p53 function by controlling p53 transcription. OM has been implicated in the process of wound healing, which involves cell proliferation, migration, and remodeling of ECM. In dermal fibroblasts, OM stimulates the production of ECM components such as collagen and glycosaminoglycan (Duncan et al., 1995) . OM has been reported to stimulate the synthesis of tissue inhibitor of metalloproteinases 1 and 3 (Kerr et al., 1999; Li et al., 2001a, b, c) . In endothelial cells, OMpromoted cell migration is associated with induction of the urokinase plasminogene activator (uPA) and uPA receptor (Strand et al., 2000) . In this study, we provide the first evidence that OM strongly induces fibronectin protein production. Analysis of fibronectin mRNA in untreated and OM-treated cells showed that OM increased the levels of fibronectin mRNA to the order of 20-30-fold (data not shown). The induction at this order of magnitude is likely to be transcriptional. Fibronectin is a multifunctional adhesive glycoprotein (Makogonenko et al., 2002) . It affects cell adhesion and migration. The OM-induced cell migration is likely to be mediated through the interaction of fibronectin with other ECM components. In MCF-7 cells, the OMinduced morphological changes, increased intrinsic cell motility, and production of fibronectin are all inhibited by DN STAT3. Our studies suggest that STAT3 signaling cascade may play important roles in ECM remodeling in breast cancer cells.
In summary, our studies have defined c-myc, cyclin D1, c/EBPd, and p53 as the downstream effectors of the OM-activated STAT3 signaling cascade that participate in the process of growth regulation. Furthermore, we have unraveled the importance of STAT3 activation in OM-induced migration of breast cancer cells and identified a new OM-regulated ECM component fibronectin. These results provide a better understanding of the molecular mechanisms whereby OM regulates cell growth and differentiation.
Materials and methods

Cells and reagents
Human breast cancer cell lines MCF-7, T47D, and SKBR-3 were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS). The T47D-dnStat3 cells were kindly provided by Dr Ali Badache at Friedrich Miescher Institute, Basel, Switzerland, and the effects of OM on these cells have been described (Badache and Hynes, 2001 ). The plasmids pEFneo and pEFneo-dnStat1 (Y701F) (Chang et al., 2000) were obtained from Dr Xin-Yuan Fu at Yale University. The plasmid pEFdnStat3 (Y705F) (Minami et al., 1996) was provided by Dr Shizuo Arika at Osaka University. The specific STAT3 luciferase reporter plasmid pLucTKS3 (Zhang et al., 1996) and the control reporter pLucTK were provided by Dr Richard Jove at the University of South Florida College of Medicine, Tampa, FL, USA. Antibodies directly to STAT3, STAT1, ERK2, cyclin D1, c/EBPd, p53, c-myc, and fibronectin were obtained from Santa Cruz and the antiphosphorylated ERK was obtained from Cell Signaling Technology.
Generation of stable clones for STAT3 and STAT1 mutant proteins
To generate stable MCF-7 clones that constitutively express an FLAG-tagged dominant negative (DN) form of STAT3 (Y705F), plasmid pEF-dnStat3 and a empty vector containing a neomycin-resistant gene (pEFneo) were cointroduced into MCF-7 cells using the transfection reagent Effectene (Qiagen, Valencia, CA, USA). Cells were selected in 300 mg/ml G418. Several clones were picked, expanded in the presence of G418, and analysed for dnSTAT3 expression with anti-FLAG antibody by immunostainning. To generate MCF-7 clones expressing a DN form of STAT1 (Y701F), plasmid pEFneodnStat1 was transfected into MCF-7 cells and several independent clones were selected and characterized for dnStat1 expression by Western blot. MCF-7-neo clones were established by introducing the empty vector pEFneo into MCF-7 cells. These clones were used as negative controls in this study.
For each stable cell lines, at least two independent clones were analysed by Western blot analysis for the expression of mutant STAT proteins, by gel shift for STAT DNA binding activity, and by growth assays to determine the response to OM treatment. Significant clonal variations were not observed.
Electrophoresis mobility shift assays (EMSA) to detect STAT DNA binding activity in cells expressing the wild-type or the mutant STAT proteins MCF-7 stable clones were seeded at 5-8 Â 10 6 cells/100 mm and cultured in medium containing 0.5% FBS overnight. Cells were then untreated or treated with OM for 15 min. Nuclear extracts were prepared by the method of Dignam et al (1983) except that the buffer A was supplemented with 1 mm Na 3 VO 4 and 1 mg per ml each pepstatin and leupeptin. Nuclear extracts were quick frozen by liquid nitrogen and stored in aliquots.
Protein concentrations were determined using a modified Bradford assay using BSA as a standard (Pierce). EMSA and supershift assays were conducted as previously described (Li et al., 2001a, b , c) using a double-stranded oligonucleotide probe (c-FosSIE) containing the high-affinity STAT-binding site (m67) derived from the c-fos gene promoter (Wagner et al., 1990) . A double-stranded oligonuleotide probe containing an SP1 binding site was used in the assay for the assessment of nonspecific bindings.
Transfection and reporter assays
Cells cultured in 24-well plates at a density of 0.12 Â 10 6 cells per well were transiently transfected with a total of 200 ng of reporter DNA and 2 ng of pRL-SV40 (Renilla, Promega) per well mixed with the Effectene reagent. Cells were switched to medium containing 0.5% FBS overnight, stimulated with OM for indicated length of time, and harvested, 24 h after transfection. Luciferase activities in total cell lysates were measured using the Promega Dual Luciferase Assay System. Absolute firefly luciferase activity was normalized against renilla luciferase activity to correct for transfection efficiency. Triplicate wells were assayed for each transfection condition and at least three independent transfection assays were performed for each reporter construct. The STAT3 luciferase reporter constructs contain seven copies of specific STAT3 binding sites corresponding to the region À123/À85 of the creactive protein (CRP) promoter (Zhang et al., 1996) . The p53 promoter luciferase reporter pGL3-p53 contains a 599 bp fragment of the human p53 promoter region and exon 1 (À426 to +172) (Li et al., 2001a, b, c) .
Cell growth assay
Cell number count was conducted in monolayer culture in 24-well Costar culture plates. Cells were plated at an initial density of 7 Â 10 3 cells/well in 0.5 ml medium supplemented with 2% FBS. OM was added 24 h after initial seeding. The culture media were replenished every 2 days. At the end of treatment, cells were trypsinized and then viable cell numbers were counted using a hemocytometer. Cell proliferation assay conducted in 96-well culture plates with an initial seeding of 2 Â 10 3 cells/well was measured using CyQUANT Cell Proliferation Assay Kit (C-7026) obtained from Molecular Probes and a fluorescence microplate reader with the parameters of 480 nm excitation and 520 nm emission.
Western blot analysis
For detection of activated ERK, cells were cultured in medium containing 0.5% FBS for overnight prior to OM stimulation. For detection of cycline D1, c/EBPd, p53, and fibronectin expression, cells were cultured in medium containing 2% FBS with or without OM for various lengths of time. Cells in 60-mm culture dishes were lysed with 0.1 ml of cold lysis buffer (20 mm HEPES, pH 7.4, 30 mm p-nitrophenyl phosphate, 10 mm NaF, 10 mm MgCl 2 , 2 mm EDTA, 5 mm dithiothreitol, 0.1 mm Na 3 VO 4 , 0.1 mm Na 2 MnO 4 , 10 mm Sodium B-glycerolphosphate, 10 nm Okadiac acid, 10 nm cypermethrin, 1 mm phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin, 1 mg/ml leupeptin, and 1.25 mg/ml pepstatin). Approximately 50 mg protein of total cell lysate per sample was separated on 10-15% SDS-PAGE, transferred to nitrocellulose membrane, followed by Western blot analysis. The signals detected using an enhanced chemiluminescence (ECL) detection system were quantitated with a BioRad Fluor-S MultiImager System. Densitometric analysis of autoradiographs in these studies included various exposure times to ensure linearity of signals.
RNA isolation and Northern blot analysis
Cells were lysed in Ultraspec RNA lysis solution (Biotecxs Laboratory, Houston, TX, USA) and total cellular RNA was isolated according to the vendor's protocol. Approximately 15 mg of each total RNA sample was used to analyse c-myc mRNA. The RNA blots were first hybridized to a 2 Kb human c-myc cDNA probe that was 32 P-labeled using the Primer-It II Random Primer Labeling kit (Stratagene) and then stripped and reprobed with a 32 P-labeled human GAPDH probe to ensure that equivalent amounts of RNA were being analysed. Hybridization signals were visualized by a BioRad PhosphorImager and were quantified by the Quantity One program.
Analysis of OM-induced morphological changes
MCF-7 and stable clones were cultured in the absence or presence of OM. At indicated times, cell morphology was examined under a phase contrast microscope equipped with a Penguin 600CL digital camera.
Migration assays
Cell motility was examined in a Boyden chamber assay using 8-mm-pore polycarbonate membrane. The migrated cells were fixed and stained using the kit Hema 3 manual staining system obtained from Fisher Scientific. Cells were counted under an inverted microscope in 10 different Â 100-power fields in triplicate wells.
Abbreviations:
ECM, extracellular matrix; EMSA, electrophoretic mobility shift assay; ERK, extracellular signal regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IL-6, interleukin-6; OM, oncostatin M; STAT, signal transducer and activator of transcription.
